Life Sciences Archive » June, 2009

Life Sciences - June, 2009

154 articles

• Solvay, Unimed Hit With AndroGel Suit In Pa.
• Some Alzheimer's Claims Tossed In Mayo Patent Suit
• Alcatel, Pfizer Still Owe Landfill Cleanup Costs: EPA
• Medtronic Sues Insurer For Worker Theft Court Costs
• EU To Consider Concessions In Pfizer, Wyeth Review
• Abbott Hit With $1.7B Verdict In IP Suit Over Humira
• Forest Derivative Appeal Halted As Sides Seek Deal
• Daiichi Sankyo Attacks Apotex Over Evoxac ANDA
• Dismissal Of AstraZeneca Securities Action Upheld
• BioMedica's Review Bid Denied In Nordic Patent Suit
• PR Campaign For IP Can Give Firms A Boost
• Roche To Stop Selling Accutane In US
• Top Fed. Circ. Rulings That Came Down Last Quarter
• Medtronic Accepts $179M Judgment In Screw Case
• Device Maker Prevails In Pain Pump Suit
• Water Board's Merck Discharge Limit Appealed
• Schering To Pay $55M To Settle AWP Suit
• FDA Enforcement Crackdown Requires Reforms
• Tug-Of-War Over Expert In Viagra Litigation Continues
• FDA Blasts Medtronic Over Slow Drug Pump Recall
• Novo Settles Danish Oil-For-Food Probe For $5.7M
• Lilly Scores 3 More Zyprexa Dismissals In MDL
• USPTO Upholds Rembrandt Contact Lens Patent
• Ariz., Drugmakers Settle Fraud Claims In AWP Suit
• FDA To Pull Immucor's Biologics License
• Abbott Sues Former Manager, Ev3 Over Trade Secrets
• FTC Says Authorized Generics Can Aid Competition
• US Marshals Seize Caraco Drugs In FDA Action
• Ky. Jury Finds Sandoz Liable For $16M In AWP Case
• AstraZeneca Strikes Out Again Over Seroquel Expert
• Sequenom Faces Slew Of Shareholder Suits
• Insurance Deal Adds $6M To Quigley Asbestos Trust
• Teva Blasts FTC's Position On Pay-For-Delay
• St. Jude Investors Can't Alter Loss Theory: Judge
• New Plaintiffs Try To Revive Medtronic ERISA Action
• St. Jude Valve Plaintiffs Lose Bid For Class Cert.
• SEC Probes Matrixx Following FDA Zicam Warning
• Bill Aims To Expand ANDA First Filer Exclusivity
• Humana Officers Prevail In Shareholders' Suit
• Fla. Appeals Court Blocks Mylan's Generic Synthroid
• Merck Moves To Block Challenge To Vioxx Settlement
• Pfizer Celebrex Suit Stayed Pending High Court Case
• Jones Day Lures Former FTC Competition Head
• Galil Sues HealthTronics In Endocare Merger Spat
• Rembrandt Vision Sues J&J Over Contact Lens Patent
• Sequenom, Beckman Drop DNA Analysis Patent Suit
• FTC Chief Says Generic-Drug Deals Cost Public $3.5B
• Rebate Discovery To Proceed In TriCor Antitrust Suit
• EU To Reveal Bank Guidance, Pharma Findings: Report
• Mailer 'Misleads' About Cancer Drug's Efficacy: FDA
• 8th Circ. Says P&G, Others Can't Jump Into CWA Suit
• Obama Taps Judges From Ga., NJ For Circuit Courts
• High Court Won't Hear 'Reverse Payment' Challenge
• FTC Issues 2nd Request In Merck-Schering Merger
• U Of Iowa Says Abbott's Humira Infringes Patents
• FDA Staff Recommends Study Of Abbott Seizure Drug
• States Join Qui Tam Medicaid Suits Against Wyeth
• Trucking Co.'s Liability Capped In Drug Shipment Loss
• Fen-Phen Attys Ordered To Pay Feds $30M
• Dismissal Of Baycol Failure-To-Warn Suit Upheld
• Novo's Suit Over Prandin ANDA Survives Bid To Toss
• Ex-Pfizer Sales Manager Sentenced For Bextra Charge
• AstraZeneca Loses Bid To Ban Seroquel MDL Expert
• Veteran White Collar Atty Returns To Fox Rothschild
• Generics Triumph Over Sanofi In Cancer Drug Quarrel
• CVS Unit's E-Ferol Insurance Spat Moved To Texas
• EU High Court Clarifies Generics Question In J&J Case
• Off-Label Marketing MDL Over Amgen Drugs Nixed
• Matrixx Braces For More Zicam Smell-Loss Suits
• Ethicon Ex-Employee Enjoined In Patent Spat
• Foley Settles Malpractice Suit Over Vaxiion Patent
• Doctor's Testimony In Own Baycol Suit 'Inadmissible'
• Cancer Suits Over Novartis Eczema Drug Remanded
• Sepracor Sues Synthon Over Oral Xyzal ANDA
• GSK Lamictal Prices Don't Breach Deal, Judge Says
• Genentech Can't Follow Up Rituxan Alone: Arbitrators
• FDA Says Zicam Nose Products Cause Loss Of Smell
• Pharma Processor Settles EPA Emissions Claims
• Ethicon Asks To Protect Patent Apps After $2M Verdict
• Norian, Synthes Charged With Illegal Human Tests
• $100M Deal Over Combe Fill Superfund Site Finalized
• Pfizer Takes On Mylan In Fight To Protect Lipitor
• Pfizer Ratchets Up Lyrica IP Suit Against Sun Pharma
• Genzyme Halts Production At Mass. Plant Over Virus
• Novo Warns Users Of Stolen Shipment Of Insulin
• Mayer Brown Grabs IP Trio From McDermott Will
• Wyeth Places Heavier Burden On Implied Preemption
• Calif., IBM Granted Most US Patents In 2008
• GSK, P&G Head For Fla. In Denture Cream MDL
• Bristol-Myers Nears Deal In Plavix Securities Suit
• Stay Granted In Lipitor Case Pending Del. Decision
• Dey Joins In Spoliation Cries In Drug Price MDL
• Allen & Overy Snags DLA, Wragge Attys For IP Group
• FDA Orders Psychiatric Warn Labels On Asthma Drugs
• Medicis Hits Ranbaxy With Acne Drug Patent Suit
• StarCaps False Advertising Suit Can Go Forward
• African Drug Importer Accused Of $1.2B Ponzi Scheme
• FDA Strengthens Gardasil Label's Fainting Warning
• 11th Circ. Finds For Roche In Accutane Suicide Suit
• Treating Physician V. Expert Witness
• Medical Device Maker Merger Battle Moves To Court
• Calif. AG, CVS Settle Inquiry Into Expired Products
• FDA Recalls 21,000 Faulty Medtronic Pacemakers
• Purdue Settles OxyContin Patent Cases Against KV
• Blackwell V. Wyeth: The Application Of Frye
• Fed. Circ. Trims Daiichi Costs Award In Levaquin Suit
• FDA Should Regulate Biologic Generics: FTC Report
• FDA Panel Says Seroquel OK For Teens
• Fed. Circ. Revives Varian Radiation Patent Fight
• NAACP Seeks Class Cert. In Lilly Race Bias Suit
• Plaintiffs Want Pfizer Celebrex Docs Unsealed
• Widow's Suit Over Wyeth Arthritis Drug Tossed
• SEC Sues Swiss Man Over Illicit Trading In GSK Deal
• Eli Lilly Moves To Toss Zyprexa Battle With Conn.
• Supreme Court Asks For SG's Take On Vaccine Suit
• Reckitt Hits Watson Again Over Mucinex ANDAs
• Allergan Launches 2nd Suit Over Combigan Patents
• CSL, Talecris Call Off $3.1B Deal Amid FTC Pressure
• Supplement Maker Sues Rival Over Disparaging Claims
• Lawmakers Slam FTC Generic Biologic Report
• ACLU Suit Spurs Debate Over Gene Patents
• Staying On Top Of Electronic Data In IP Cases
• Abbott Accuses DOJ Of 'Massive' Spoliation
• Actavis Seeks To Narrow Subpoena In Digitek MDL
• WL Gore Indefiniteness Defense Shot Down In IP Suit
• GSK, Inventor Urge Fed. Circ. To Review Tafas V. Doll
• Texas Court Affirms Tossing Of $26M Vioxx Judgment
• Genentech — Where Do We Go From Here?
• Teva Access To Pfizer Docs On Detrol Restricted
• Judge OKs Synergetics Tying Claims Against Alcon
• Gilead Shareholders Must Amend Suit For 5th Time
• The New Geography Of Patent Litigation
• Lilly Wins 2 Summary Judgment Bids In Zyprexa MDL
• Walgreen To Pay $1.4M To End Cold Remedy Ad Suit
• Schering Contractors' Trade Secrets Spat Revived
• FDA Finds Liver Risk In Generic Graves' Treatment
• P&G, McNeil-PPC Settle Teeth-Whitening Patent Spat
• Mayer Brown Puts Associates To Work In-House
• Suit Claims Teva's Wellbutrin Generic Is Inferior
• Wyeth Workers Seek Summary Judgment In FLSA Suit
• FDA Takes Step Toward Increased Transparency
• P&G, AstraZeneca Sued Over Prilosec OTC Risks
• On Securities, Sotomayor Sticks To 'Nuts And Bolts'
• Contact Lens Cleaner Settlements Cost Bausch $250M
• FTC Pushes Congress To Pass Drug Settlement Bill
• 3rd-Party Microsoft Claims Survive In Web Patent Suit
• IP Attys Hail Cert Grant On Bilski
• Fed. Circ. Cuts $226M Award In Medtronic Screw Suit
• Blood Reagent Buyers Put J&J, Immucor In Hot Seat
• Bid To Replead Medtronic Securities Suit Denied
• Eastern Texas After TS Tech, Awaiting Genentech
• Dueling Patents Partly Invalidated In Lexapro Row
• Fed. Circ. Rules Enbrel Doesn't Infringe Ariad Patent
• Discrimination V. Whistleblower Claims